Yoshizaki, Kazuyuki

Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo

Atreya, R., Mudter, J., Finotto, S., Müllberg, J., Jostock, T., Wirtz, S., Schütz, M., Bartsch, B., Holtmann, M., Becker, C., et al. (2000) · Nature Medicine

Inflammatory Bowel DiseaseCytokine Signaling Pathways and Interactions

Cited by 1,293

Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease

Yoshizaki, K., Matsuda, T., Nishimoto, N., Kuritani, T., Taeho, L., Aozasa, K., Nakahata, T., Kawai, H., Tagoh, H., & Komori, T. (1989) · Blood

Viral-associated cancers and disordersLymphadenopathy Diagnosis and Analysis

Cited by 928

Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease

Nishimoto, N., Kanakura, Y., Aozasa, K., Johkoh, T., Nakamura, M., Nakano, S., Nakano, N., Ikeda, Y., Sasaki, T., Nishioka, K., et al. (2005) · Blood

Viral-associated cancers and disordersAutoimmune and Inflammatory Disorders Research

Cited by 754

TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling

Becker, C., Fantini, M. C., Schramm, C., Lehr, H. A., Wirtz, S., Nikolaev, A., Burg, J., Strand, S., Kiesslich, R., Huber, S., et al. (2004) · Immunity

TGF-β signaling in diseasesCytokine Signaling Pathways and Interactions

Cited by 726

Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial

Choy, E. H. S., Isenberg, D. A., Garrood, T., Farrow, S., Ioannou, Y., Bird, H., Cheung, N., Williams, B., Hazleman, B., Price, R., et al. (2002) · Arthritis & Rheumatism

Rheumatoid Arthritis Research and TherapiesAutoimmune and Inflammatory Disorders Research

Cited by 526

IL-6 is required for the development of Th1 cell-mediated murine colitis

Yamamoto, M., Yoshizaki, K., Kishimoto, T., & Ito, H. (2000) · The Journal of Immunology

Inflammatory Bowel DiseasePsoriasis: Treatment and Pathogenesis

Cited by 411

Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease

Song, S.-N. J., Tomosugi, N., Kawabata, H., Ishikawa, T., Nishikawa, T., & Yoshizaki, K. (2010) · Blood

Iron Metabolism and DisordersAutoimmune and Inflammatory Disorders Research

Cited by 228

Comparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients

Song, S.-N. J., Iwahashi, M., Tomosugi, N., Uno, K., Yamana, J., Yamana, S., Isobe, T., Ito, H., Kawabata, H., & Yoshizaki, K. (2013) · Arthritis Research & Therapy

Iron Metabolism and DisordersRheumatoid Arthritis Research and Therapies

Cited by 143

ANTI-INTERLEUKIN 6 (IL-6) RECEPTOR ANTIBODY SUPPRESSES CASTLEMAN'S DISEASE LIKE SYMPTOMS EMERGED IN IL-6 TRANSGENIC MICE

Katsume, A., Saito, H., Yamada, Y., Yorozu, K., Ueda, O., Akamatsu, K.-I., Nishimoto, N., Kishimoto, T., Yoshizaki, K., & Ohsugi, Y. (2002) · Cytokine

Cytokine Signaling Pathways and InteractionsRheumatoid Arthritis Research and Therapies

Cited by 134

Effects of IL-6, adiponectin, CRP and metabolic syndrome on subclinical atherosclerosis

Nishida, M., Moriyama, T., Ishii, K., Takashima, S., Yoshizaki, K., Sugita, Y., & Yamauchi-Takihara, K. (2007) · Clinica Chimica Acta

Adipokines, Inflammation, and Metabolic DiseasesCardiovascular Health and Disease Prevention

Cited by 86